Gyre Therapeutics (NASDAQ:GYRE) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.07) by 42.86 percent. The company reported quarterly sales of $22.519 million which missed the analyst consensus estimate of $31.607 million by 28.75 percent. This is a 2.09 percent increase over sales of $22.058 million the same period last year.